News | April 06, 2022
Revenue growth to moderate, non-Covid-19 revenue to drive profitability
Ind-Ra maintains a neutral outlook for healthcare in FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
The new facility is scheduled to start operation in the first half of 2024
Trescal provides precision calibration expertise in every industry, geography and instrument across the world
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Phablecare closed this acquisition for an undisclosed sum, betting on the start-up's holistic approach to Type 1 Diabetes management
He will continue to lead business in LATAM and Asia regions in this new role
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The companies plan to use the proceeds to retire debt and expand operations
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
